Bionano Genomics, Inc. Warrant
BNGOW
BNGOW was delisted on the 17th of August, 2023.
2 hedge funds and large institutions have $5K invested in Bionano Genomics, Inc. Warrant in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
78% less capital invested
Capital invested by funds: $23K → $5K (-$18K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$22K |
BNGOW Hedge Fund Activity: Q3 2022 in Review
2 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics, Inc. Warrant (BNGOW) for Q3 2022, worth a combined $5K — down 78% from $23K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BNGOW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $5.4K. The largest seller was Privium Fund Management, exiting entirely with an estimated $22K sold.
- 2 institutional investors held Bionano Genomics, Inc. Warrant (BNGOW) as of Q3 2022, down from 3 in Q2 2022.
- Funds reported $5K of Bionano Genomics, Inc. Warrant stock for Q3 2022, down 78% quarter-over-quarter.
- 0 funds opened new Bionano Genomics, Inc. Warrant positions in Q3 2022 and 1 closed out, a net change of -1 holder.
- The largest Bionano Genomics, Inc. Warrant buyer in Q3 2022 was UBS Group, an estimated $5.4K added.
- The largest Bionano Genomics, Inc. Warrant seller in Q3 2022 was Privium Fund Management, an estimated $22K sold.
Based on aggregated 13F filings for Q3 2022.